Employers are tired of feeling confused or overwhelmed by the data provided from their pharmacy benefit manager (PBM). In our latest Fast Five post, we’re uncovering what makes up a stellar reporting package from a PBM, including essential data points for employer groups and the pitfalls of overwhelming clients with too much data.
We’ve been seeing employers hesitate to move to a new pharmacy benefit manager (PBM) for fear of the impact on their members. In this Fast Five, we share what it’s really like for employers and their employees to move to a better PBM (like EpiphanyRx) with a supportive transition approach.
EpiphanyRx performed a study to identify drivers contributing to recent increased ADHD medication use within commercial employer groups. Read more about our discoveries.
In this Fast Five, we revisit biosimilars - still a hot industry topic. We explore biosimilar pricing and the incentives motivating drug manufacturers and pharmacy benefit managers (PBMs). We discuss formulary decisions including placement of biosimilars and removal of brand Humira®. To help us break down this complicated topic, we consulted our clinical expert, Janelle Sheen, Senior Director of Clinical Strategy.
GPOs began emerging in 2019 and continue to grow. In this Fast Five, we share five insights on transparency in the age of GPOs and what to keep in mind when you are evaluating different PBMs.
EpiphanyRx studied the refill success rates for preventive medications as a measure of adherence in HDHPs across our book of business. Learn more about what we discovered.
While some pharmacy benefit managers (PBMs) have been talking about transparency for years, it has become an increasingly hot topic in the health care industry. So what does transparency really mean? Let’s take a fast five (minutes) to look at PBM pricing models and how transparency comes into play.
Everyone is hearing a lot about prescription drug pricing lately thanks to a very famous billionaire entrepreneur. What is cost-plus pricing? Is it new? How is it disrupting the industry? In this Fast Five, we share answers to these questions and provide guidance on how to evaluate this model. For a smart insider’s perspective, we consulted with Sharon Faust, Senior Vice President, Lumicera Specialty Pharmacy.
Making a pharmacy benefit manager (PBM) transition can be a daunting task especially for busy benefit teams. We consulted our internal implementation experts on what a smooth transition looks like and how the right partner will provide reassurance that you are making the right move.
